| Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free! |
AIM-listed pharmaceutical firm Shield Therapeutics (LON:STX) has seen its share price drop by 3.55% to 109.55p (as of 13:05 BST) after legal proceedings were lodged against it. Teva Pharmaceuticals has filed an appeal to the Opposition Division of the European Patent Office regarding the decision on a patent held by Shield.
Management said that the company will defend its intellectual property and believe that the board of appeal should uphold the original decision.